Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxybutynin is a small molecule antimuscarinic and anticholinergic agent used to treat symptoms of overactive bladder such as urinary urgency, frequency, incontinence (urine leakage), and increased night-time urination. It works by relaxing the detrusor muscle of the bladder through antagonism of muscarinic acetylcholine receptors (primarily M3 subtype), thereby reducing involuntary contractions and increasing bladder capacity. Oxybutynin is also indicated for neurogenic detrusor overactivity associated with neurological conditions like spina bifida in children. It is available as immediate-release tablets or syrup (oral), extended-release tablets (oral), topical gel (Gelnique), and transdermal patch (Oxytrol)[1][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxybutynin.